8 Results for "

PDZ1

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "PDZ1" in MCE Product Catalog:

Cat. No.: HY-124813
CAS No.: 2083618-79-3
Purity:  99.29%
Synonyms: 113B7
Target:  

FAK EGFR MMP NF-κB SDCBP

Research Areas:  

Cancer

PDZ1i (113B7) is a inhibitor of MDA-9/Syntenin, with selective binding to the PDZ1 domain. PDZ1i inhibits radiation-induced invasion of glioblastoma (GBM) cells, radiosensitizes GBM cells, and impairs GBM-related signaling pathways (including Src/EphA2, EGFRvIII/FAK, and NF-κB). PDZ1i reduces radiation-induced secretion of invasion-related proteases (MMP-2, MMP-9, ADAM9). PDZ1i shows anti-tumor effects in nude mice bearing intracranial U1242-luc xenografts or GBM xenografts. PDZ1i can be used for the study of glioblastoma (GBM), breast cancer and prostate cancer [1] .
loading...
    loading...
Cat. No.: HY-P1195
CAS No.: 1315378-73-4
Target:  

iGluR

Research Areas:  

Neurological Disease

PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain [1].
loading...
    loading...
Cat. No.: HY-P1195A
Target:  

iGluR

Research Areas:  

Neurological Disease

PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain [1].
loading...
    loading...
Cat. No.: HY-150269
CAS No.: 2227017-46-9
Research Areas:  

Cancer

RS5517 is a specific PDZ1-domain antagonist of NHERF1 that prevented its ectopic nuclear entry. RS5517 can be used for the research of colorectal cancer [1] .
loading...
    loading...
Cat. No.: HY-P10331
CAS No.: 2757292-12-7
Target:  

SDCBP

Research Areas:  

Cancer

KSL 128114, a peptide inhibitor of syntenin, binds the PDZ1 domain of syntenin with nanomolar affinity. KSL 128114 is resistant toward degradation in human plasma and mouse hepatic microsomes and displays a global PDZ domain selectivity for syntenin [1].
loading...
    loading...
Cat. No.: HY-156247
Target:  

SDCBP NF-κB MMP

Research Areas:  

Cancer

IVMT-Rx-3 is a inhibitor of SDCBP targeting of the PDZ1 and PDZ2 Domains of MDA-9/Syntenin. IVMT-Rx-3 blocks MDA-9/Syntenin interaction with Src, reduces NF-κB activation, and inhibits MMP-2/MMP-9 expression. IVMT-Rx-3 inhibits Melanoma Metastasis [1]
loading...
    loading...
Cat. No.: HY-162510
Target:  

NF-κB

Research Areas:  

Cancer

SPDZi1 is a potent and selective syntenin inhibitor that binds to PDZ1 and PDZ2 domains of syntenin. SPDZi1 binds to the syntenin PDZ tandem (STNPDZ) with a Kd of 3.6 μM. SPDZi1 suppresses glioblastoma and reduces the activation of NF-κB, a downstream effector of syntenin [1].
loading...
    loading...
Cat. No.: HY-182624
CAS No.: 873841-43-1
Research Areas:  

Cancer

FJ9 is a NHERF1/PDZ inhibitor with human NHERF1 PDZ1 IC50 1540 μM, NHERF1 PDZ2 IC50 160 μM, and Frizzled-7-Dishevelled PDZ complex Ki 10 μM. FJ9 binds ligand-binding pockets of NHERF1 PDZ domains to block cognate ligand interactions, disrupts Frizzled-7-Dishevelled interactions, and down-regulates canonical Wnt signaling. FJ9 induces apoptosis in cancer cells with intact β-catenin signaling. FJ9 can be used for the research of non-small cell lung cancer, melanoma [1] .
loading...
    loading...